We use essential cookies (authentication, your saved goals/stack) by default. With your permission we'll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
4 peer-reviewed studies
What the evidence says
Most Acarbose studies are mechanism or observational rather than RCTs that measure a clinical effect — keep findings provisional.
Most evidence is from medium-quality randomised trials published 2003–2016 with a typical study size of 1,429 participants.
Based on 4 studies · 2 RCTs · 1,429 total participants
Confidence
LowBy outcome
Newest study from 2016
Acarbose reduced the risk of cardiovascular disease and hypertension in people with impaired glucose tolerance.
Chiasson, Josse, Gomis, Hanefeld, Karasik, Laakso · Diabetologia (2004)
Acarbose treatment lowered the risk of cardiovascular disease and hypertension in glucose-intolerant patients.
Chiasson, Josse, Gomis, Hanefeld, Karasik, Laakso · JAMA (2003)
A weakly estrogenic agonist (17α-estradiol) produced longer lifespan in male mice.
Strong, Miller, Antebi, Astle, Bogue, Denzel · Aging cell (2016)
Acarbose is an oral anti-diabetes drug with additional cardiovascular benefits.
Hanefeld, Schaper · Expert review of cardiovascular therapy (2008)